Comparative Evaluation of Diatherix Target Enriched Multiplex Polymerase Chain Reaction and BioFire FilmArray in the Detection of Viral and Bacterial Respiratory Pathogens

Chen, Wei‐Ju; Arnold, John H.; Fairchok, Mary; Hansen, Erin; Malone, Leslie; Grigorenko, Elena L.; Stalons, Donald; Milzman, Jacqueline Owens; Ridoré, Michelande; Coles, Christian; Burgess, Timothy; Millar, Eugene V.

doi:10.1093/ofid/ofw172.105

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sensitivity and specificity for pathogen identification are 96.2% and 98.3% for BAL, and 96.3% and 97.2% for sputum specimens, and for detecting antibiotic resistance, 100% and 98.5%, respectively [ 24 ]. Diatherix target enriched multiplex PCR (TEM-PCR) (TEMPCR™; Diatherix Laboratories, Inc.; Huntsville, AL) is another respiratory target-enriched multiplex panel that covers nine viruses and fifteen bacterial pathogens ( Acinetobacter baumannii, Bordetella pertussis, Chlamydophila pneumoniae, H. influenza, H. influenzae (type B), Klebsiella pneumoniae, Legionella pneumophilae , Moraxella catarrhalis, S. aureus , MRSA, Panton-Valentine leukocidin gene, Mycoplasma pneumoniae, Neisseria meningitides, Pseudomonas aeruginosa , and Streptococcus pneumoniae ) with a rapid turnaround time of 8 to 12 h from receipt of the specimen from the upper and lower respiratory tract [ 25 ]. This latter has not been FDA-approved yet.…”

Section: Microbiological Diagnosismentioning

confidence: 99%

Diagnosis of Multidrug-Resistant Pathogens of Pneumonia

Sfeir

2021

Diagnostics

View full text Add to dashboard Cite

Hospital-acquired pneumonia and ventilator-associated pneumonia that are caused by multidrug resistant (MDR) pathogens represent a common and severe problem with increased mortality. Accurate diagnosis is essential to initiate appropriate antimicrobial therapy promptly while simultaneously avoiding antibiotic overuse and subsequent antibiotic resistance. Here, we discuss the main conventional phenotypic diagnostic tests and the advanced molecular tests that are currently available to diagnose the primary MDR pathogens and the resistance genes causing pneumonia.

show abstract

Section: Microbiological Diagnosismentioning

confidence: 99%

Diagnosis of Multidrug-Resistant Pathogens of Pneumonia

Sfeir

2021

Diagnostics

View full text Add to dashboard Cite

show abstract

The Acute Respiratory Infection Consortium: A Multi-Site, Multi-Disciplinary Clinical Research Network in the Department of Defense

et al. 2019

View full text Add to dashboard Cite

Introduction Acute respiratory infections (ARI) result in substantial annual morbidity among military personnel and decrease operational readiness. Herein, we summarize the research efforts of the Infectious Disease Clinical Research Program (IDCRP) related to ARIs. Methods The ARI Research Area of the IDCRP was established in response to the 2009 emergence of pandemic influenza A/H1N1. That year, IDCRP investigators deployed the ARI Consortium Natural History Study (ARIC NHS), a multi-centered, longitudinal observational study to assess etiology, epidemiology, and clinical characteristics of influenza-like illness (ILI) and severe acute respiratory infections (SARI) in the U.S. military. The success of this initial effort spurred implementation of several new initiatives. These include the FluPlasma trial, designed to evaluate the efficacy of hyperimmune anti-influenza plasma for the treatment of severe influenza; the self-administered live-attenuated influenza vaccine (SNIF) trial, which assessed the immunogenicity and acceptance of a self-administered live-attenuated influenza vaccine in military personnel; the Study to Address Threats of ARI in Congregate Military Populations (ATARI), a prospective study of ILI transmission, etiology and epidemiology in recruits; and the Flu Breath Test (FBT) study, a preliminary study of exhaled volatile organic compounds (VOC) in influenza patients. In addition, the InFLUenza Patient-Reported Outcome (FLU-PRO) survey, a daily diary to measure influenza symptoms during clinical trials, was developed. Lastly, the Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED) study, a two-year randomized trial designed to compare the effectiveness of the three types of licensed vaccines, launched in Fall 2018. Results The on-going ARIC NHS has enrolled over 2000 ILI and SARI cases since its inception, providing data on burden and clinical manifestations of ARI in military personnel and their families. The FluPlasma 2 trial concluded subject enrollment in 2018. Preliminary results from ATARI study show a high frequency of respiratory viruses circulating during the first two weeks of recruit training. Based on assessment of FLU-PRO responses, which were found to be reliable and reproducible, the survey may be a useful tool in clinical trials and epidemiological studies. The Flu Breath Study will complete enrollment in 2019. Findings from PAIVED are intended to provide evidence needed for assessing influenza vaccination policy in the military. Conclusions The ARI burden in the armed services remains significant every year and the threat is dynamic given emergent and evolving threats, such as influenzas. With strong successes to date, future initiatives of the ARI Research Area will focus on interventional studies, ARI transmission dynamics in congregate military settings, and determinants of risk of pandemic influenza and other emergent respiratory viruses.

show abstract

Comparative Evaluation of Diatherix Target Enriched Multiplex Polymerase Chain Reaction and BioFire FilmArray in the Detection of Viral and Bacterial Respiratory Pathogens

Cited by 2 publications

References 0 publications

Diagnosis of Multidrug-Resistant Pathogens of Pneumonia

Diagnosis of Multidrug-Resistant Pathogens of Pneumonia

The Acute Respiratory Infection Consortium: A Multi-Site, Multi-Disciplinary Clinical Research Network in the Department of Defense

Contact Info

Product

Resources

About